Revenue
2019
Kalaris Therapeutics, Inc. (KLRS)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $165,000 |
| Research & development | $30.8M | $45.0M | $133.1M | $118.9M | $120.7M | $49.7M | $16.2M |
| Operating expenses | $46.2M | $51.7M | $199.9M | $171.2M | $169.8M | $71.3M | $26.9M |
| Operating income | −$46.2M | −$51.7M | −$199.9M | −$171.2M | −$169.8M | −$71.3M | −$26.7M |
| EBITDAderived | — | — | −$199.5M | −$170.5M | −$169.6M | −$71.2M | −$26.7M |
| Net income | −$43.4M | −$69.2M | −$190.4M | −$168.7M | −$172.0M | −$69.8M | −$23.8M |
| Basic EPSper diluted share | -$2.85 | -$51.77 | -$42.09 | -$2.20 | -$2.74 | -$2.59 | -$18.54 |
| Diluted EPSper diluted share | -$2.85 | -$51.77 | -$42.09 | -$2.20 | -$2.74 | -$2.59 | -$18.54 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 20, 2026Form 4 | Samsara BioCapital, L.P. +4TenPercentOwner | BuyCommon Stock · indirect | 244.3K | $4.83 | $1.18M | 2.22M |
| Mar 20, 2026Form 4 | Hagen Brett RChief Accounting Officer | SellCommon Stock | 1.9K | $6.72 | $12.9K | 0 |
| Dec 18, 2025Form 4 | Samsara Opportunity Fund, L.P. +4TenPercentOwner | BuyCommon Stock · indirect | 479.8K | $10.42 | $5.00M | 1.98M |
| Mar 26, 2025Form 4 | Hagen Brett RChief Accounting Officer | SellCommon Stock | 907 | $8.97 | $8.1K | 1.9K |
| Feb 21, 2025Form 4 | Sinha VikasSee Remarks | SellCommon Stock | 303 | $10.08 | $3.1K | 49.1K |